fair value is not possible to say now..., page-6

Hello dossantd, Boiler and everyone,
The post from abandon1 is very interesting and is hopefully fairdinkum. dossantd, you make a very relevant point re the potential for the SP going higher and I do agree.

There are legitimate comparisons with Dendreon which can give us some insight into the process Prima will travel and SP possibilities for the future. In this respect we compare dilution, patent life, orphan designation, trial stages etc. etc. However, recently a more interesting aspect for me, when comparing Dendreon and Prima has to do with their specific patents and their use after US FDA NDA approval, if given.

It is my understanding that Provenge is primarily for the treatment of prostate cancer alone, while Cvac has shown success in early trials for a number of cancers as Muc-1 is located in a number of cancers apart from Ovarian such as:

colon, pancreatic, breast, renal cell carsinoma (Kidney...), transitional cell carcinoma (urinary system..., multiple myeloma (white blood cells), non-small cell lung (most comman form of lung cancer)

There are quite a few trials being conducted on, or relating in some way to Muc-1, and statements at the investor presentation and in recent announcements by Prima management regarding the use of Cvac post US FDA NDA approval and the size of the whole US cancer market is for me, a sign of their confidence in the potential for Cvac to be used by oncologist for treatment of a number of different cancers.

Add to this Dendreons commencement of phase II trials with Provenge for the treatment of prostate cancer pre surgery and chemotherapy, and the use of these immunotherapy treatments becomes more accepted as part of the overall battle against cancer.

http://www.bio-medicine.org/medicine-technology-1/Dendreon-Initiates-Phase-2-Trial-of-PROVENGE-in-Patients-With-Localized-Prostate-Cancer-Prior-to-Surgery-2645-1/

That is why any speculation of SP is difficult. There has been rumour of a Dendreon take-over at $40 per share and buy recommendation in the US for Dendreon in the $30's.

There are so many variables. But most importantly phase IIb/III must be successful and also orphan disease designation needs to be granted to add further value. All of this is still some way off, so who really knows what the SP could be, or if some other discovery is made to treat cancer..........

But firstly and most importantly, let eligable shareholders support Prima through the current Share Purchase Plan. This is a huge opportunity and one which could really assist Prima.

Regards

dc